RESEARCH

Is Frailty Index a better predictor than pre-stroke modified Rankin Scale for neurocognitive outcomes 3-months post-stroke?

Ragnhild Munthe-Kaas¹²*, Stina Aam³⁴, Ingvild Saltvedt³⁴, Torgeir Bruun Wyller²⁵, Sarah T. Pendlebury⁶⁷, Stian Lydersen⁸, Guri Hagberg⁹, Till Schellhorn²¹⁰, Siri Rostoft²⁵ and Hege Ihle-Hansen¹²⁹

Abstract

Background: The prognostic value of frailty measures for post-stroke neurocognitive disorder (NCD) remains to be evaluated.

Aims: The aim of this study was to compare the predictive value of pre-stroke FI with pre-stroke modified Rankin Scale (mRS) for post-stroke cognitive impairment. Further, we explored the added value of including FI in prediction models for cognitive prognosis post-stroke.

Methods: We generated a 36-item Frailty Index (FI), based on the Rockwood FI, to measure frailty based on pre-stroke medical conditions recorded in the Nor-COAST multicentre prospective study baseline assessments. Consecutive participants with a FI score and completed cognitive test battery at three months were included. We generated Odds Ratio (OR) with NCD as the dependent variable. The predictors of primary interest were pre-stroke frailty and mRS. We also measured the predictive values of mRS and FI by the area (AUC) under the receiver operating characteristic curve.

Results: 598 participants (43.0% women, mean/SD age = 71.6/11.9, mean/SD education = 12.5/3.8, mean/SD pre-stroke mRS = 0.8/1.0, mean/SD GDS pre-stroke = 1.4/0.8, mean/SD NIHSS day 1 3/4), had a FI mean/SD score = 0.14/0.10. The logistic regression analyses showed that FI (OR 3.09), as well as the mRS (OR 2.21), were strong predictors of major NCD. When FI and mRS were entered as predictors simultaneously, the OR for mRS decreased relatively more than that for FI. AUC for NCD post-stroke was higher for FI than for mRS, both for major NCD (0.762 vs 0.677) and for any NCD (0.681 vs 0.638).

Conclusions: FI is a stronger predictor of post-stroke NCD than pre-stroke mRS and could be a part of the prediction models for cognitive prognosis post-stroke.

Trial Registration: ClinicalTrials.gov Identifier: NCT02650531.

Keywords: Stroke, Cognition, Cognitive Impairment, Frailty, Prediction

*Correspondence: Ragnhild.Munthe-Kaas@studmed.uio.no; Ragnhild.Munthe-Kaas@vestreviken.no

² Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Full list of author information is available at the end of the article

Background

One out of four stroke survivors fulfills the criteria for major post-stroke neurocognitive disorder (NCD) after one year [1], and any post-stroke NCD is reported to be up to 53% in hospital-based studies[2].
Health status, disability and cognition pre-stroke are important prognostic factors in a stroke population. Predictors of different cognitive outcomes are needed to target interventions preventing cognitive decline, and to provide optimal care post-stroke. Vascular risk factors, stroke related factors, and frailty measures are addressed in existing prediction models of post-stroke NCD [3, 4].

People age biologically at different rates [5, 6]. Frailty is a condition of vulnerability associated with an increased risk of adverse health outcomes such as functional decline and mortality. A gradual decline in physiological reserves is expected with age, but in frailty, this decline is accelerated and occurs in various organ systems. The many scales for measuring frailty reflect the uncertainty regarding the best way to assess this syndrome [7]. There are, however, two main theories of the definition of frailty [5]. In the model by Fried and colleagues, the so-called physical frailty phenotype is described as a clinical syndrome [8]. Presence of three or more of the following symptoms: weight loss, weakness, slowness, fatigue and low physical activity defines frailty. Fried et al.'s phenotype does not take cognitive status into account. The second theory, developed by Rockwood and colleagues, describes frailty by measuring accumulated deficits across multiple systems such as comorbidity, physical function, nutritional status, and cognitive function [9]. Based on the number of deficits, it is possible to calculate a Frailty Index (FI), and a higher index indicates more pronounced frailty and predicts adverse outcomes [5].

In stroke, the modified Rankin scale (mRS) is often used for measuring pre-stroke dependency [10]. However, the scale is somewhat crude, focused on mobility, and lacks information on comorbidity and cognitive function [11]. Pre-stroke mRS is a well-known tool for assessing premorbid ability for selection of patients in stroke studies, but the relation to cognitive outcome post-stroke is fairly studied. The mRS does not take into account the heterogeneity seen in older adults, which may be better reflected by measuring frailty.

Frailty measures have demonstrated their prognostic accuracy for mortality and general outcomes in many fields of medicine, but remain to be tested for prognostication of post-stroke NCD. Studies have shown an association between frailty and cognitive impairment in a general population [12, 13], and between frailty and vascular dementia [14].

Aims

In the Norwegian Cognitive Impairment after Stroke (Nor-COAST) study, we aimed to compare the predictive value of pre-stroke FI with pre-stroke mRS for post-stroke cognitive impairment.

Further, we explored the added value of including pre-stroke FI in prediction models for cognitive prognosis post-stroke.

Methods

The Nor-COAST study is a multicenter prospective cohort study recruiting consecutive participants in the acute phase of stroke from five Norwegian stroke units 2015–2017. The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK) North, (REC number 2015/171) [15]. Participants gave informed written consent; if unable to give consent, informed written consent was given by a family proxy. Further details are described in the protocol article for the Nor-COAST study [3].

Demographic characteristics, such as age, sex and years of education, vascular risk factors, National Institutes of Health Stroke Scale (NIHSS) score, acute stroke progression and infections treated with antibiotics, were collected at baseline [3].

Baseline brain magnetic resonance imaging (MRI) were assessed for white matter hyperintensities (WMH) and medial temporal lobe atrophy (MTA). WMH were rated according to the Fazekas scale [16]. MTA was rated according to the Scheltens scale [17].

Pre-stroke global function was described by the mRS, a seven-level scale running from zero up to six, covering the entire range of functional outcomes from no symptoms to death [18].

The trained study nurses based the assessment of pre-stroke function on an unstructured interview.

Cognition

Premorbid cognitive status was based on Global Deterioration Scale (GDS) [19], a global measure of cognitive function using all available information from cognitive and functional tests and self-/proxy reporting [15]. By description of the behavioral characteristics of the stroke survivor given by the patient him/herself or his/her proxy, the pre-stroke cognitive state was graded by trained study nurses into stage 1–7 at the GDS scale. Patients with pre-stroke NCD were not excluded from this study.

At 3-month follow-up, cognitive function was assessed with a 30 min neurocognitive test battery, based on the National Institute of Neurological Disorders-Canadian Stroke Networks Harmonization Standards [20], validated and adapted for Norwegian participants. The following cognitive domains were assessed: complex attention (Trail Making Test A-TMT-A), executive function (Trail Making Test B-TMT-B and Verbal Fluency Test Letters-FAS), memory (Word List Delayed Recall), language (Verbal Fluency Test Category-animals), and
perceptual-motor function (visuospatial/executive subtest of Montreal Cognitive Assessment) [15, 21]. NCD was defined according to the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [22] criteria. Published international normative data from high-income Western countries comparable to Norway were used. Participants performing ≥ 1.5 SD below the normative mean in ≥ one of the five cognitive domains were defined as having any post-stroke NCD, as described in detail in a previous paper [15, 22–24].

Major NCD was defined as post-stroke NCD and dependency in instrumental activities of daily living (I-ADL); mild NCD was defined as post-stroke NCD without impairments in I-ADL. I-ADL was defined, according to the DSM-5, as the ability to manage own finances and handle their own medications (from a study question to participants) [15].

**The Frailty Index**

The Rockwood FI score [5] is a simple calculation of the presence or absence of each health deficit, ranged 0–1, as a proportion of the total [6]. The FI contains a number of equally weighted deficits across different domains [25]. When at least 30 variables are included, FI is shown to be a robust predictor of mortality [26].

We generated the 36-item FI to measure frailty based on pre-stroke medical conditions, symptoms or problems recorded in the Nor-COAST baseline assessments [27, 28]. The FI was conducted post-hoc. All domains described in the original Rockwood FI were represented in our list of pre-specified conditions except the domain of walking speed. In some domains we had to do adjustments from the original FI, as we lacked information in the baseline data. This was the case regarding detailed function pre-stroke, and accordingly we used dichotomized mRS scores for this purpose, as described in the additional file. We also lacked information regarding the ability to walk 800 m, as we only had collected information on the ability to walk 200 m (See Additional file 1). For further details on generation of the FI, please see Additional file 1.

The FI score was computed using the coding shown in Additional file 1, Table I. For patients with available coding on at least 30 variables, the sum was divided by the number of codings. The resulting score was between 0.0 and 1.0, where a higher score represented more severe frailty. The FI is not meant to be dichotomized into frail and robust, but Rockwood and colleagues have earlier demonstrated in their work that 0.25 can be an empirical cut-off between robust and frail [29]. For a descriptive presentation in this study, the participants were categorized as ‘robust’ if FI was below 0.08, ‘pre-frail’ if FI was between 0.08 and 0.24, and ‘frail’ if FI was higher than 0.24, in line with earlier work on frailty [29, 30]. The pre-frail state represents an elevated risk for becoming frail [30].

**Statistical analyses**

We used logistic regression with cognitive impairment at 3-months as the dependent variable. Cognitive impairment was defined as a three category ordinal variable (normal, mild and major NCD). Preliminary analysis with ordinal logistic regression showed that the Odds Ratio (OR) for FI was higher for major than for mild impairment (test of parallel lines, p = 0.014). Hence, we used two sets of binary logistic regression analyses, one for each threshold; normal or mild vs major NCD (major NCD) and normal vs any NCD (any NCD).

The predictors of primary interest were pre-stroke frailty (full range FI) and pre-stroke mRS (ordinal scale). We reported the OR for frailty per 0.1 increase in FI. We chose to report OR per 0.1 unit on the scale, since the observed frailty index varies over some multiples of 0.1, and this is also the standard deviation of frailty in our study.

Note that the OR for FI and the OR for mRS cannot directly be compared, since these are measured on different scales.

We carried out a sensitivity analysis excluding the component “cognitive function” from the computation of the FI.

We measured the predictive values of pre-stroke mRS and FI by the area (AUC) under the receiver operating characteristic (ROC) curve. We estimated the added value of FI compared to pre-stroke mRS in terms of increased AUC, using the “somersd” command in the add-on package snp15_7 in Stata 16. This method accounts for the fact that part of pre-stroke mRS was included in the FI, and these are associated, as described in the Additional file 1.

The logistic regression analyses were carried out unadjusted, and adjusted for the following variables, one at a time: Age, sex, years of education, NIHSS score, acute stroke progression, infections treated with antibiotics, Fazekas score and MTA score. Missing values were handled using available case analysis, that is, in each analysis, we included all patients with data on the variables in that analysis (Tables 1 and 4). Ninety-five percent confidence intervals (CI) were reported where relevant, and we regarded a two-sided p-value < 0.05 to represent statistical significance. The aim in the Nor-COAST study was to include 1000 patients, which after expected drop out of about 25% was estimated to retain sufficient power for the main research questions, as described in the protocol article [3]. Except where otherwise noted, statistical analyses were carried out using SPSS 25.
Table 1 Baseline characteristics, N = 598

| Demographics                                      |         |
|---------------------------------------------------|---------|
| Mean/SD age, years                               | 71.6/11.9 |
| Female sexa                                       | 257 (43.0) |
| Mean/SD education, years                         | 12.5/3.8 |
| Mean/SD pre-stroke mRSb                          | 0.8/1.0 |
| Mean/SD GDS pre-strokec                          | 1.4/0.8 |
| TOAST classification                              |         |
| Large-vessel disease                              | 54 (10.2) |
| Cardioembolic disease                             | 123 (23.3) |
| Small-vessel disease                              | 120 (22.7) |
| Other etiology                                    | 14 (2.7) |
| Undetermined etiology                             | 217 (41.1) |
| Assessments                                       |         |
| Mean/SD NIHSS (0–42) day 1e                       | 3/4     |
| Mean/SD mRS at admittancef                       | 2.06/1.3 |
| Mean/SD Frailty Index baseline                   | 0.14/0.10 |
| Frailty Grade                                     |         |
| Robust                                            | 140 (23.4) |
| Pre-frail                                         | 367 (61.4) |
| Frail                                             | 91 (15.2) |
| Complications in the acute phase                  |         |
| Acute stroke progressiong                        | 42 (7.3) |
| Infection treated with antibioticsg                | 63 (10.6) |
| MRI findings acute phase                         |         |
| Fazekas pathology                                 | 118 (34.1) |
| MTA pathology                                     | 112 (32.4) |

SD Standard deviation, mRS modified Rankin Scale, TOAST Trial of Org 10,172 in Acute Stroke Treatment, NIHSS National Institutes of Health Stroke Scale, MRI Magnetic resonance imaging, MTA Medial Temporal Atrophy

* numbers are n (%), unless otherwise specified

a N = 597
b N = 595
c N = 528
d N = 588
e N = 596 576
f N = 576 594
g N = 594 346
h 346

i Fazekas pathology were rated according to the Fazekas scale [16]

j MTA was rated according to the Scheltens scale [17]

Results

Of the 815 participants included at baseline in the NOR-COAST study, a total of 598 participants (43.0% women, mean/SD age = 71.6/11.9, mean/SD education = 12.5/3.8, mean/SD pre-stroke mRS = 0.8/1.0, mean/SD GDS pre-stroke = 1.4/0.8, mean/SD NIHSS day 1 3/4) had both FI at baseline and completed neurocognitive test battery at 3-months (Table 1, Fig. 1, see also Additional File 1) [15] in whom mean/SD FI score was 0.14/0.10. Of these, 140 (23.4%) participants were assessed as robust, 367 (61.4%) as pre-frail and 91 (15.2%) as frail (Table 1). The distribution of frailty in the different age groups showed an increasing number of pre-frail and frail patients in the higher age-groups (Fig. 2). The proportion with pre-stroke dementia assessed by GDS was 22 (3.7%) (Additional file 1 (Table II)).

The results of logistic regression with NCD as dependent variable and FI or pre-stroke mRS or both as predictors, are shown in Table 2. The FI, as well as the pre-stroke mRS, were strong predictors of both major NCD (OR 3.09 and 2.21) and any NCD (OR 2.29 and 1.89). When FI and pre-stroke mRS were entered as predictors for major NCD simultaneously, however, the OR for pre-stroke mRS decreased relatively more (to 1.24) than the OR for FI (to 2.67). A sensitivity analysis excluding the component “cognitive function” from the computation of the FI gave practically the same results (OR for FI vs pre-stroke mRS for major NCD; 2.97 vs 2.20, and for any NCD; 2.22 vs 1.87), see also Additional file 1 (Table III).

The predictive values, measured as area under the ROC curve, were higher for FI than for pre-stroke mRS (Table 3). This applied to both major NCD (0.762 vs 0.677) and any NCD (0.681 vs 0.638). The difference in AUC was 0.086 (CI 0.042 to 0.129), p < 0.001, for major NCD, and 0.043 (CI 0.002 to 0.083), p = 0.039 for any NCD. Hence, the added predictive value of FI over pre-stroke mRS was larger for major NCD than for any NCD.

The logistic regression analysis for any NCD 3-months post-stroke for frailty baseline showed an OR (OR per 0.1 unit increase in FI) at 2.29 (CI 1.83 to 2.87). The estimates remained approximately the same when adjusting for age, sex, education, NIHSS score, acute stroke progression, infections, Fazekas or MTA pathology (Table 4).

Discussion

We demonstrated that pre-stroke FI is a stronger predictor than pre-stroke mRS for post-stroke major NCD. Moreover, pre-stroke frailty is a strong and independent predictor for any NCD post-stroke.

There are no general guidelines for interpreting AUC values, but the rule of thumb used by Hosmer et al. 2013 [31] indicates that an increase of 0.1 or more in AUC may be considered important, and that an AUC over 0.7 represents acceptable discrimination [31]. In sum, our study indicates that pre-stroke FI is clearly better in predicting

**Table 1** Baseline characteristics, N = 598

Demographics

|                             |         |
|-----------------------------|---------|
| Mean/SD age, years          | 71.6/11.9 |
| Female sexa                 | 257 (43.0) |
| Mean/SD education, years    | 12.5/3.8 |
| Mean/SD pre-stroke mRSb     | 0.8/1.0 |
| Mean/SD GDS pre-strokec     | 1.4/0.8 |
| TOAST classification        |         |
| Large-vessel disease        | 54 (10.2) |
| Cardioembolic disease       | 123 (23.3) |
| Small-vessel disease        | 120 (22.7) |
| Other etiology              | 14 (2.7) |
| Undetermined etiology       | 217 (41.1) |
| Assessments                 |         |
| Mean/SD NIHSS (0–42) day 1e| 3/4     |
| Mean/SD mRS at admittancef | 2.06/1.3 |
| Mean/SD Frailty Index baseline | 0.14/0.10 |
| Frailty Grade               |         |
| Robust                      | 140 (23.4) |
| Pre-frail                   | 367 (61.4) |
| Frail                       | 91 (15.2) |
| Complications in the acute phase |         |
| Acute stroke progressiong  | 42 (7.3) |
| Infection treated with antibioticsg | 63 (10.6) |
| MRI findings acute phase   |         |
| Fazekas pathology           | 118 (34.1) |
| MTA pathology               | 112 (32.4) |

SD Standard deviation, mRS modified Rankin Scale, TOAST Trial of Org 10,172 in Acute Stroke Treatment, NIHSS National Institutes of Health Stroke Scale, MRI Magnetic resonance imaging, MTA Medial Temporal Atrophy

* numbers are n (%), unless otherwise specified

a N = 597
b N = 595
c N = 528
d N = 588
e N = 596 576
f N = 576 594
g N = 594 346
h 346

i Fazekas pathology were rated according to the Fazekas scale [16]

j MTA was rated according to the Scheltens scale [17]
post-stroke major NCD than pre-stroke mRS, whereas the difference is not so convincing regarding any NCD.

Different well-known risk factors and mechanisms are thought to play an important role in developing post-stroke NCD, hereby the stroke severity and the brain resilience. Brain resilience is described, partly as cognitive reserve (age, education, lifestyle factors) and partly as brain reserve. Brain reserve is explained by individual differences in brain size and chronic brain pathological changes [32]. In our prediction model, we adjusted for these potential confounding variables operationalized as white matter lesions (Fazekas score) and atrophy (MTA score). Age is the only risk factor that, to some degree, influences the effect of FI both for developing major NCD and for any NCD. Other risk factors did not modify the effect of frailty.

An association between frailty and NCD has also been observed in non-stroke populations. The association has only to a very limited degree been studied in stroke populations, though with essentially the same results as we showed in this study [25, 33]. Mechanisms from dysfunction in multiple organ systems are discussed to contribute in the development of post-stroke NCD, and our results extend the findings of previous work in this field, by demonstrating the strong association between frailty and NCD.

Moreover, we found a high occurrence of pre-stroke frailty, with almost 80% of the population being pre-frail or frail before the incident stroke. This is in line with findings in a similar study of frailty in a stroke population [30, 34], and should be an important factor when planning for treatment, secondary prevention and rehabilitation.

The mRS is a well-established tool in stroke medicine, both for research and in clinical settings. Pre-stroke mRS assess premorbid function for selection of patients for stroke studies, but the relation to cognitive outcome post-stroke remains to be evaluated. If the mRS had shown to be equal to the FI for predicting post-stroke
NCD, the introduction of another tool for stroke medicine would have been unnecessary.

During the last decade, frailty assessments have become a mainstay in geriatric medicine. Our findings imply that frailty assessments deserve their place in stroke medicine in prediction of cognition as well as overall prognosis, and potentially as a part of clinical decision-making regarding acute treatment for stroke. Future studies are needed to address the latter [35]. A full FI assessment might be time consuming, and a short version, like the Clinical Frailty Scale [7] exists, but the predictive value needs to be evaluated in stroke patients. Like the mRS, Clinical Frailty Scale might be too crude and lose predictive value compared to a full FI.

We recognize there is a debate over the definition of frailty and inclusion of cognition in the concept. Therefore, comparing the predicting value of Fried et al’s phenotype and the FI based on Rockwood for post-stroke NCD would be of interest in future studies. Further, as patients with pre-stroke NCD were included in the study, the term “marker” for post-stroke NCD could have been more precise than “predictor”. However, “predictor” is consistent with its use in the meaning of “covariate” [36] or “explanatory variable” [37].

This study has some limitations. First, we assessed pre-stroke frailty post-hoc, based on information acquired post-stroke, partly by proxies. We used information about the ability to manage own finances in the FI score and

### Table 2

| OR for Major NCD | OR for Any NCD |
|------------------|---------------|
| Frailtya 3.09 (2.45 to 3.89), < 0.001 | 2.29 (1.83 to 2.87), < 0.001 |
| mRS 2.21 (1.83 to 2.68), < 0.001 | 1.89 (1.56 to 2.29), < 0.001 |

* OR per 0.1 units increase in the Frailty index (FI)

### Table 3

| AUC (CI), p-value |
|-------------------|
| Major NCD | Any NCD |
|------------------|---------------|
| Frailty 0.762 (0.717 to 0.808), < 0.001 | 0.681 (0.638 to 0.723), < 0.001 |
| mRS 0.677 (0.626 to 0.727), < 0.001 | 0.638 (0.598 to 0.678), < 0.001 |
| Difference 0.086 (0.042 to 0.129), < 0.001 | 0.043 (0.002 to 0.083), 0.039 |

ROC Receiver operating characteristic curve, AUC Area under the curve, CI Confidence interval, NCD Neurocognitive disorder, mRS modified Rankin Scale
also as an I-ADL measure for cognition. Moreover, we used the pre-stroke mRS score as a means for assessing functional status as part of the FI score, and at the same time as comparator for the FI (Additional file 1). However, the statistical analyses account for all these issues. The pre-stroke mRS was assessed by unstructured interview by study nurses, which may reduce the inter-rater reliability when compared with structured assessments [11]. The generalizability of our analyses may be more valid for patients who had experienced milder strokes, as the study population had similar baseline characteristics but better pre-stroke health and milder strokes than the non-included stroke patients [38].

A strength is that we in this study used FI for assessing frailty, which is reproducible, highly correlated with mortality, and easily calculated, as part of a structured multi-professional assessment that should be routine in every stroke unit.

Conclusions
In this study, frailty was a stronger predictor than pre-stroke mRS for post-stroke NCD. Measures of frailty could be a part of the prediction models for cognitive prognosis post-stroke.

Table 4 Logistic regression analysis with major NCD or Any NCD as dependent variable*

|                          | Major NCD OR (95% CI) | Any NCD OR (95% CI) |
|--------------------------|-----------------------|---------------------|
| Frailty unadjusted       | 3.09 (2.45 to 3.89)   | 2.29 (1.83 to 2.87) |
| Frailty adjusted separately for |                      |                     |
| Age                      | 2.52 (1.98 to 3.20)   | 2.01 (1.58 to 2.55) |
| Sex                      | 3.08 (2.44 to 3.88)   | 2.29 (1.83 to 2.87) |
| Education                | 2.87 (2.27 to 3.63)   | 2.11 (1.68 to 2.65) |
| NIHSS sum score at admittanceb | 3.13 (2.46 to 3.94)   | 2.26 (1.80 to 2.84) |
| Acute stroke progressionc | 3.11 (2.45 to 3.94)   | 2.28 (1.81 to 2.87) |
| Infection treated by antibioticsd | 2.98 (2.36 to 3.76)   | 2.25(1.79 to 2.83) |
| Fazekas pathologya       | 3.44 (2.47 to 4.80)   | 2.17 (1.59 to 2.97) |
| MTA pathologyf           | 3.66 (2.63 to 5.10)   | 2.27 (1.69 to 3.06) |

NCD Neurocognitive disorder, NIHSS National Institutes of Health Stroke Scale, MTA Medial Temporal Atrophy
a All p-values were <0.001
bunless otherwise specified
b N=587
c N=576
*N=594
N=346 for major NCD, N=333 for mild or major NCD
f N=346

Abbreviations
NCD: Neurocognitive disorder; FI: Frailty Index; mRS: Modified Rankin Scale; the Nor-COAST study; the Norwegian Cognitive Impairment after Stroke study; MRI: Magnetic resonance imaging; WMH: White matter hyperintensities; MTA: Medial temporal lobe atrophy; GDS: Global Deterioration Scale; NIHSS: National Institutes of Health Stroke Scale; TMT: Trail Making Test; DSM-5: The 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders; I-ADL: Instrumental activities of daily living; OR: Odds Ratio; AUC: Area under the receiver operating characteristic curve; ROC: Receiver operating characteristic curve; CI: Confidence interval.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12877-022-02840-y.

Additional file 1: Table I. Comprehensive Geriatric Assessment-Based Frailty Index. Table II. Cognitive status pre-stroke based on Global Deterioration Scale (GDS) † N=595. Table III. Logistic regression analysis with NCD as dependent variable, and Frailty (‘cognitive function’ excluded from the frailty index) and mRS as predictors. N= 596.

Acknowledgements
We thank all participants, the dedicated study staff at the Clinical Trial Unit in all the participating hospitals and the Nor-COAST research group.

Authors’ contributions
IS manages the Nor-COAST study. IS and HiH had the idea for the design of the present study. RMK and HiH were responsible for writing the present report with additional critical input from the co-authors. SA developed the workup for the diagnostic algorithm for cognition; RMK, HiH and SL performed the statistical analysis. All authors interpreted the data and read and approved the final manuscript.

Funding
The Nor-COAST study is funded by the Norwegian Health Association, and Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Science, NTNU-Norwegian University of Science and Technology. The authors are funded elsewhere: RMK by the Vestre Viken Hospital Trust. STP is supported by the NIHR Oxford Biomedical Research Centre, UK.

Availability of data and materials
Study data are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK) North, (REC number 2015/171). All methods were performed in accordance with the relevant guidelines and regulations. Participants gave informed written consent; if unable to give consent, informed written consent was given by a family proxy.

Consent for publication
Not applicable.

Competing interests
IS was an investigator in the Boehringer-Ingelheim trial 1346.0023. The other authors have no disclosures.

Author details
1Department of Medicine, Baerum Hospital, Vestre Viken Hospital Trust, Drammen, Norway. 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Science, NTNU-Norwegian University of Science and Technology, Trondheim, Norway. 4Department of Geriatric Medicine, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
References

1. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. The Lancet. Neurology. 2009;8(11):1006–18.

2. Barbay M, Douf M, Roussel M, Godefroy O. Systematic review and meta-analysis of prevalence in post-stroke neurocognitive disorders in hospital-based studies. Dement Geriatr Cogn Disord. 2018;46(S6–6):322–34.

3. Thingstad P, Aukland T, Beyer MK, Brathen G, Ellekjaer H, Ihle-Hansen H, et al. The Norwegian Cognitive impairment after stroke study (Nor-COAST): study protocol of a multicentre, prospective cohort study. BMC Neurosci. 2018;19(1):193.

4. Pendlebury ST. Stroke-related dementia: rates, risk factors and implications for future research. Maturitas. 2009;64(3):165–71.

5. Rockwood K, Hovell SE. Age-related deficit accumulation and the diseases of ageing. Mech Ageing Dev. 2019;180:107–16.

6. Gordon EH, Hubbard RE. Differences in frailty in older men and women. Med J Aust. 2020;212(4):183–8.

7. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95.

8. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Grotti G, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.

9. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323–36.

10. Harrison JK, McArthur KS, Quinn TJ. Assessment scales in stroke: clinimetric and clinical considerations. Clin Interv Aging. 2013;8:201–11.

11. Fearen P, McArthur KS, Garry K, Graham LJ, McGroarty G, Vincent S, et al. Pre-stroke Modified Rankin Stroke Scale has moderate interobserver reliability and validity in an acute stroke setting. Stroke. 2012;43(12):3184–8.

12. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment—a review of the evidence and causal mechanisms. Ageing Rev. 2013;12(4):840–51.

13. Armstrong JJ, Godin J, Launer LJ, White LR, Mitnitski A, Rockwood K, et al. Changes in frailty predict changes in cognition in older men: the Honolulu-Asia aging study. J Alzheimers Dis. 2016;53(3):1003–13.

14. Solfirizi V, Scalfati E, Friardi V, Seripa D, Logroscino G, Maggi S, et al. Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging. Alzheimer’s Dementia. 2013;9(2):113–22.

15. Munthe-Kaas R, Aam S, Ihle-Hansen H, Lydersen S, Knapskog AB, Wyller TB, et al. Impact of different methods defining post-stroke neurocognitive disorder: The Nor-COAST study. Alzheimers Dement (N Y). 2020;6(1):e12000.

16. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–6.

17. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vernooij MW, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1994;55(10):967–72.

18. Broderick JP, Adeoye O, Elin J. Evolution of the modified rankin scale and its use in future stroke trials. Stroke. 2017;48(7):2007–12.

19. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.

20. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyrenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41.

21. Sachdev PS, Lo JW, Crawford JD, Mellion L, Hickey A, Williams D, et al. STROKOG (stroke and cognition consortium): an international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimers Dement (Amst). 2017;7:11–23.

22. Association AP. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington D.C: American Psychiatric Association; 2013.

23. Knopman DS, Gottesman RF, Sharrett AR, Wuu LM, Windham BG, Coker L, et al. Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016;2:1–11.

24. Sachdev PS, Lipnicki DM, Crawford JD, Brodaty H. The vascular behavioral and cognitive disorders criteria for vascular cognitive disorders: a validation study. Eur J Neurol. 2019;26(9):1161–7.

25. Evans NR, Todd GW, Minhas JS, Fearon P, Harston GW, Mant J, Mead G, Hewitt J, Quinn TJ, Warburton EA. Frailty and cerebrovascular disease: Concepts and clinical implications for stroke medicine. Int J Stroke. 2021;17:47493921034331. https://doi.org/10.1177/174749321034331. Epub ahead of print.

26. Mitnitski A, Song X, Skoog I, Broe GA, Cox JL, Grunfeld E, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(2):184–9.

27. Frailty Indexes, oversatt til norsk: Legeforeningen; 2019 [cited 2020 2110]. Available from: https://www.legeforeningen.no/contentassets/c8609a1992b472097c7c8baf88acada/frailtyindeks_norsk_endelig_230519.pdf

28. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24.

29. Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. J Gerontol A Biol Sci Med Sci. 2007;62(7):738–43.

30. Taylor-Roan M, Cuthbertson G, Keir R, Shaw R, Drozdowski B, Elliott E, et al. The prevalence of frailty among acute stroke patients, and evaluation of method of assessment. Clin Rehabil. 2019;33(10):1688–96.

31. Hooimeijer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. John Wiley & Sons; 2013.

32. Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. Nat Rev Neurol. 2017;13(3):148–59.

33. Taylor-Roan M, Keir R, Cuthbertson G, Shaw R, Drozdowski B, Elliott E, et al. Pre-Stroke frailty is independently associated with post-stroke cognition: a cross-sectional study. Int J Neuropsychol Soc. 2019;23(5):501–6.

34. Palmer K, Vetrano DL, Padua L, Romano V, Rivoiro C, Scelfo B, et al. Frailty syndromes in persons with cerebrovascular disease: a systematic review and meta-analysis. Front Neurol. 2019;10:1255.

35. Drouard-de Roussiers E, Lucas L, Richard S, Consoli A, Mazigi M, Labreuche J, et al. Impact of reperfusion for nonagenarians treated by Mechanical Thrombectomy: insights from the ETIS Registry. Stroke. 2019;50(1):1364–9.

36. Day S. Dictionary for clinical trials 2ed. Chichester, England: John Wiley & Sons; 2007.

37. Everitt B. Medical statistics from A to Z. A guide for clinicians and medical students. 2nd ed. Cambridge: Cambridge University Press; 2006.

38. Kvodis RR, Salvedt I, Aam S, Thingstad P, Ellekjaer H, Askim T. The Risk of Selection Bias in a Clinical Multi-Center Cohort Study. Results from the Norwegian Cognitive Impairment After Stroke (Nor-COAST) Study. Clin Epidemiol. 2020;12:1327–36.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.